Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

17.8%

13 terminated/withdrawn out of 73 trials

Success Rate

78.0%

-8.5% vs industry average

Late-Stage Pipeline

63%

46 trials in Phase 3/4

Results Transparency

78%

36 of 46 completed trials have results

Key Signals

7 recruiting36 with results6 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 3
26(37.1%)
Phase 4
20(28.6%)
Phase 2
18(25.7%)
Phase 1
5(7.1%)
N/A
1(1.4%)
70Total
Phase 3(26)
Phase 4(20)
Phase 2(18)
Phase 1(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (73)

Showing 20 of 73 trials
NCT03997786Phase 2Active Not Recruiting

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Role: lead

NCT03897075Phase 3Completed

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Role: lead

NCT06611163Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Role: lead

NCT04066504Completed

Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma

Role: lead

NCT07282743Phase 2Recruiting

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Role: lead

NCT07385547Phase 1Recruiting

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

Role: lead

NCT04314531Phase 3Active Not Recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Role: lead

NCT04991116Phase 3Active Not Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Role: lead

NCT03992729Recruiting

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Role: lead

NCT06425900Phase 4Active Not Recruiting

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Role: lead

NCT04566666Phase 2Completed

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Role: lead

NCT04314544Phase 3Completed

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Role: lead

NCT06415305Phase 4Completed

A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Role: lead

NCT04684485Phase 2Completed

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

Role: lead

NCT06336603Phase 4Completed

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Role: lead

NCT05561634Phase 2Recruiting

Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

Role: collaborator

NCT06880848Phase 4Completed

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

Role: collaborator

NCT06336629Phase 4Completed

A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Role: lead

NCT06952517Phase 2Recruiting

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Role: collaborator

NCT06415279Phase 4Completed

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Role: lead